Melanotan 1 Dosage: How Much to Take, When & How

Melanotan 1 Dosage: How Much to Take, When & How

Overview

Melanotan 1 (afamelanotide) is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH), triggering melanin production without UV exposure. It works by binding to melanocortin-1 receptors (MC1R) on melanocytes, activating a cellular signaling cascade that increases skin pigmentation and provides photoprotection.

The compound is available in two primary forms: a 16 mg biodegradable subcutaneous implant (FDA-approved as Scenesse for erythropoietic protoporphyria) and injectable research-grade preparations dosed at 0.5–1 mg per injection. This guide focuses on practical dosing protocols for both clinical and research applications.

Important Disclaimer: This content is educational only and does not constitute medical advice. Melanotan 1 is prescription-only in many jurisdictions. Consult a licensed healthcare provider before use, and never self-administer without proper medical supervision, especially given the requirement for dermatological monitoring of existing moles and nevi.

Standard Dosing Protocol

Implant-Based Dosing (FDA-Approved Clinical)

Dose: 16 mg (biodegradable subcutaneous implant)
Frequency: One implant every 60 days
Route: Subcutaneous injection
Duration: The implant gradually releases peptide over approximately 60 days, providing continuous dosing without repeated injections.

This is the only FDA-approved form for erythropoietic protoporphyria (EPP) and is administered under medical supervision by a healthcare provider.

Injectable Dosing (Research/Off-Label Use)

For research and off-label applications, injectable Melanotan 1 follows a different protocol than the implant:

Initial Loading Phase:

• Dose: 0.5–1 mg per injection
• Frequency: Daily or every-other-day injections
• Duration: 7–14 days (loading period)

Maintenance Phase:

• Dose: 0.5–1 mg per injection
• Frequency: 2–3 times per week
• Duration: Ongoing, adjusted based on response

The loading phase accelerates melanin production and skin darkening. Many users report noticeable pigmentation changes within the first week. The maintenance phase sustains the achieved tan and photoprotection.

Dosing by Goal

For Photoprotection in Photosensitive Conditions

Recommended Dose: 16 mg implant every 60 days (clinical) or 0.5–1 mg injections daily for 10–14 days followed by 2–3 times weekly (research)

Rationale: Clinical trials in EPP patients demonstrate that consistent Melanotan 1 dosing significantly increases phototoxic burn tolerance—from a median of 15 minutes to 250 minutes of sunlight exposure. Quality of life scores improved from baseline averages of 11–44% to 75–79%, indicating robust photoprotection.

Expected Timeline: Observable skin darkening within 7–10 days; maximum photoprotection develops over 2–4 weeks of consistent dosing.

For Cosmetic Skin Darkening

Recommended Dose: 0.5–1 mg daily or every-other-day for 10–14 days (loading), then 2–3 times weekly (maintenance)

Rationale: Cosmetic darkening occurs through the same melanin-stimulation mechanism. Users typically achieve visible tanning without UV exposure or tanning bed use. One human trial (n=24) showed that Melanotan 1 + low-dose UV-B significantly enhanced tanning and maintained it at least 3 weeks longer than sunlight-only controls, with 47% fewer sunburn cells.

Expected Timeline: Noticeable pigmentation change within 3–7 days; full tan depth reached by day 14–21.

For Dermatological Conditions (Acne, Solar Urticaria)

Recommended Dose: 0.5–1 mg daily for 7–14 days, then 2–3 times weekly

Rationale: Small pilot studies demonstrate anti-inflammatory effects. In one acne trial (n=3), all patients showed significant reduction in inflammatory lesions by day 56, with improved quality of life scores and only mild transient fatigue reported. In a solar urticaria study (n=5), increased melanin density correlated with reduced urticarial responses, with minimum urticarial dose rising 1–12 increments by day 30.

Expected Timeline: Anti-inflammatory benefits typically emerge over 2–4 weeks as skin pigmentation deepens.

How to Administer

Subcutaneous Injection Technique

1. Preparation:

   • Use sterile, pharmaceutical-grade vials only
   • Reconstitute lyophilized (freeze-dried) peptide with sterile bacteriostatic water or saline per product instructions
   • Allow 30 minutes for full reconstitution
   • Store reconstituted solution at 2–8°C (refrigerated)

2. Injection Site:

   • Rotate injection sites: abdomen, thigh, upper arm, or hip
   • Clean injection site with 70% isopropyl alcohol; allow to air-dry
   • Use a 30-gauge, 0.5-inch needle for subcutaneous administration

3. Administration:

   • Pinch skin at injection site to create a fold
   • Insert needle at a 45-degree angle into the fatty tissue layer
   • Inject slowly over 5–10 seconds
   • Withdraw needle and apply gentle pressure; do not massage

4. Post-Injection:

   • Minor pain, redness, or bruising at the injection site is normal and typically resolves within 24–48 hours
   • Alternate injection sites to minimize irritation and induration (hardening)

Implant Administration

Implant placement is a minor surgical procedure performed by a healthcare provider:

• A small incision is made, typically on the upper arm or abdomen
• The 16 mg biodegradable implant is inserted subcutaneously
• The incision is closed with standard sutures
• Sutures are typically removed 7–10 days post-placement

Cycling & Timing

Continuous vs. Cycled Dosing

Continuous Dosing (Standard): Many users maintain steady Melanotan 1 dosing year-round with the loading + maintenance protocol. This approach sustains consistent skin pigmentation and photoprotection without seasonal breaks.

Seasonal Cycling: Some users adopt a seasonal approach, intensifying dosing during high-sun exposure seasons (spring/summer) and reducing maintenance frequency during winter months. This mirrors natural UV exposure patterns and may reduce injection frequency costs.

Implant Cycling: The 16 mg implant delivers approximately 60 days of continuous dosing. Timing depends on when you need peak photoprotection:

• Spring/summer protection: Place implant 2 weeks before peak sun exposure season
• Year-round: Administer new implants every 60 days continuously

Timing Within the Day

Injection Timing:

• Inject at the same time each day (or every other day) to maintain stable blood levels
• Optimal time is early morning or late afternoon; some users report less nausea when injected with food
• Avoid injecting directly before intense physical activity or hot environments, as facial flushing may occur within 30–60 minutes

Beginner vs. Advanced Dosing

Beginner Protocol

Week 1–2 (Loading):

• 0.5 mg daily or every-other-day
• Single injection site per day (rotate sites daily)
• Target: 7–14 total injections during loading phase

Week 3+ (Maintenance):

• 0.5 mg, 2–3 times per week (e.g., Monday, Wednesday, Friday)
• Continue rotating injection sites
• Monitor for nausea, flushing, or injection site reactions

Rationale: Conservative starting doses minimize nausea and allow assessment of individual tolerance before advancing.

Advanced Protocol

Week 1–2 (Loading):

• 1 mg daily
• Faster pigmentation development
• Requires higher tolerance to potential side effects

Week 3+ (Maintenance):

• 1 mg, 2–3 times per week
• Or: 0.5–1 mg daily at lower frequency for sustained suppression of photosensitivity symptoms

Rationale: Experienced users tolerate higher doses and prioritize faster results or stronger photoprotection.

Common Dosing Mistakes

1. Skipping the Loading Phase

   • Administering only maintenance doses (2–3 times weekly) without initial daily dosing delays pigmentation by 2–3 weeks
   • Always perform 7–14 days of daily or every-other-day dosing to establish baseline melanin production

2. Inconsistent Maintenance Timing

   • Irregular injection spacing (e.g., 3 days one week, 5 days the next) causes uneven pigmentation and reduced photoprotection
   • Stick to a fixed schedule: Mon/Wed/Fri, or Tue/Thu/Sat patterns ensure consistency

3. Overdosing on Maintenance

   • Injecting more than 3 times weekly during maintenance does not accelerate results and increases side effect risk
   • More frequent dosing beyond clinical protocols (which use implants every 60 days) is not backed by evidence

4. Using Expired or Poorly Stored Reconstituted Solution

   • Reconstituted peptide degrades if stored at room temperature or beyond 14 days
   • Always refrigerate at 2–8°C and discard after 14 days

5. Rotating Injection Sites Poorly

   • Injecting in the same location repeatedly causes bruising, induration, and reduced absorption
   • Use a systematic rotation: Day 1 abdomen, Day 2 thigh, Day 3 arm, Day 4 hip, then repeat

6. Administering Too Close to Bedtime

   • Nausea peaks 30–60 minutes post-injection; injecting in the evening may disrupt sleep
   • Inject in the morning or early afternoon, ideally with food

Dosing Summary Table

Key Takeaways

• Implant users receive consistent, hands-off dosing with one 16 mg implant every 60 days
• Injectable users follow a loading phase (0.5–1 mg daily for 7–14 days) followed by maintenance (2–3 times weekly)
• Beginners should start with 0.5 mg doses to assess tolerance; advance to 1 mg if side effects are minimal
• Dosing mistakes—skipping loading, inconsistent timing, overdosing maintenance, poor site rotation—are common and undermine results
• Cost ranges from $60–$300 per month depending on dose, frequency, and supplier
• Dermatological monitoring is essential, as Melanotan 1 can stimulate hyperpigmentation of pre-existing moles and nevi

Always obtain Melanotan 1 from reputable, verified sources and use only under medical supervision. Self-administration of research-grade peptides carries risks related to product purity, sterility, and accurate dosing, as well as the inability to monitor for serious skin changes without professional oversight.